The Effect of Chloroquine on Pro-Inflammatory Cytokines Levels in Graves’ Disease: Historical Cohort from a Pilot Randomized Controlled Trial


Objectives: Analyzing the trend in the serum inflammatory cytokines levels in a historical cohort of patients treated with combination of chloroquine and methimazole. Material and methods: We analyzed the pro-inflammatory serum cytokines level [Interleukin-6(IL-6), Tumor Necrosis Factor alpha (TNF-α), Interleukin 1 alpha (IL-1 α) and Interferon gamma (INF-γ)] in the stored blood samples of 22 patients with Graves’ disease who previously randomized to receive either chloroquine and methimazole combination therapy or methimazole monotherapy. Total T3, T4 and TSH levels were measured by an enzyme linked immunosorbent assay (ELISA) method (DRG, New York, USA) and the result was published previously. In this study we used an ELISA method (Bender Medsystem Vienna Austria) to measure serum pro-inflammatory cytokines in the first 6 months of trial. Results: No significant differences in serum cytokines concentration were observed between the two treatment groups (p > 0.05). Although it was not statistically significant, serum INF-gamma concentration tended to be lower in the chloroquine group after four months of therapy (p = 0.12). Conclusion: In this study we found changes in the serum thyroid hormones level did not accompany concomitant changes in the serum cytokines levels in two treatment groups. Therefore it is possible that chloroquine reduce serum thyroid hormones levels independent of its immunomodulatory effect.

Share and Cite:

H. Moattar, H. Moosapour, A. Soltani and B. Larijani, "The Effect of Chloroquine on Pro-Inflammatory Cytokines Levels in Graves’ Disease: Historical Cohort from a Pilot Randomized Controlled Trial," Pharmacology & Pharmacy, Vol. 4 No. 4, 2013, pp. 392-397. doi: 10.4236/pp.2013.44056.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] A. P. Weetman, “Graves’ Disease,” New England Journal of Medicine, Vol. 343, No. 17, 2000, pp. 1236-1248. doi:10.1056/NEJM200010263431707
[2] D. S. Cooper, “Hyperthyroidism,” Lancet, Vol. 362 No. 9382, 2003, pp. 459-468. doi:10.1016/S0140-6736(03)14073-1
[3] D. Sugru, M. Mcevoy, J. Feely and M. I. Drury, “Hyperthyroidismin the Land of Graves’: Results of Treatment by Surgery, Radio-Iodine and Carbimazole in 837 Cases,” The Quarterly Journal of Medicine, Vol. 49, No. 193, 1980, pp. 51-61.
[4] J. A. Franklyn, “The Management of Hyperthyroidism,” New England Journal of Medicine, No. 330, 1994, pp. 1731-1738. doi:10.1056/NEJM199406163302407
[5] A. P. Weetman and L. DeGroot, “Autoimmunity to the Thyroid Gland,” In: L. J. De Groot, Ed., Thyroid Disease Manager, Endocrine Education, Chicago, 1999.
[6] A. P. Weetman, R. Bright-Thomas and M. Freeman, “Regulation of Interleukin-6 Release by Human Thyrocytes,” Journal of Endocrinology, Vol. 127, No. 2, 1990, pp. 357-361. doi:10.1677/joe.0.1270357
[7] G. Aust, M. Heuer, S. Laue, I. Lehmann, A. Hofmann, N. E. Heldin and W. A. Scherbaum, “Expression of Tumor Necrosis Factor-Alpha (TNF-α) mRNA and Protein in Pathological Thyroid Tissue and Carcinoma Cell Lines,” Clinical & Experimental Immunology, Vol, 105, No. 1, 1996, pp. 148-154. doi:10.1046/j.1365-2249.1996.d01-726.x
[8] R. N. Maini, B. Grubeck-Loebenstein, M. Field, C. Q. Chu, E. Abney, R. Q. Zheng and M. Feldmann, “Detection of Interleukin-6 and Interleukin-1 Production in Human Thyroid Epithelial Cells by Non-Radioactive in Situ Hybridization and Immunohistochemical Methods,” Clinical Experimental Immunology, Vol. 83, No. 2, 1991, pp. 314-319.
[9] L. Kayser, H. Broholm, D. Francis, H. Perrild, B. E. Olsen, K. Bendtzen and P. E. Heyer, “Immunocytochemical Localisation of Tumor Necrosis Factor Alpha in Thyroid Tissues from Patients with Neoplastic or Autoimmune Thyroid Disorders,” Autoimmunity, Vol. 23, No. 2, 1996, pp. 91-97. doi:10.3109/08916939608995332
[10] M. Feldmann, J. R. Lamb, R. N. Maini, M. Field, C. Q. Chu, E. R. Abney and R. Q. Zheng, “Detection of in Vivo Production of Tumour Necrosis Factor-Alpha by Human Thyroid Epithelial Cells,” Immunology, Vol. 75, No. 3, 1992, pp. 456-462.
[11] L. Cleik, S. Alkalin and T. Ebra, “Serum Level of InterLeukin_6 and Tumor Necrosis Factor_Alpha in Hyperthyroid Patient before and after Propylthiouracil Treatment,” European journal of Endocrinology, Vol. 132, No. 6, 1995, pp. 668-672. doi:10.1530/eje.0.1320668
[12] P. Lakato, J. Folds, C. Harvath, L. Kiss, A. Tatrai, I. Takaes, J. Tarjan and P. H. Stern, “Serum Interleukin_6 and Bone Metabolism in Patient with Thyroid Function Disorder,” Journal of Clinical Endocrinololgy and Metabolism, Vol. 82, No. 1, 1997, pp. 78-81.
[13] A. Siddiqi, J. P. Monson, D. F. Wood, G. M. Besser and J. M. Burrin, “Serum Cytokines in Thyrotoxicosis,” Journal of Clinical Endocrinology and Metabolism, Vol. 84, No. 2, 1999, pp. 435-439. doi:10.1210/jc.84.2.435
[14] A. Akalin, O. Colak, O. Atalas and B. Efe, “Bone Remodelling Markers and Serum Cytokines in Patients with Hyperthyroidism,” Clinical Endocrinology (Oxford), Vol. 57, No. 1, 2002, pp. 125-129.
[15] A. Bossowski, M. Urban, A. Koput, M. Gardzieiczyk, J. Wysocka and S. Kreczko, “Serum Levels of Interleukin 6 (IL-6) and Soluble IL-6 Receptor (sIL-6R) in Children and Adolescents with Graves-Basedow Disease,” Endokrynologia Diabetologia i Choroby Przemiany Materii Wieku Rozwozowego, Vol. 5, No. 2, 2003, pp. 85-93.
[16] A. Bossowski and M. Urban, “Serum Levels of Cytokines in Children and Adolescents with Graves’ Disease and Non-Toxic Nodular Goiter,” Journal of Pediatric Endocrinology and Metabolism, Vol. 14, No. 6, 2001, pp. 741747. doi:10.1515/JPEM.2001.14.6.741
[17] R. Pichler, W. Maschek, M. Hatzl-Griefsenhofer, M. Huber, C. Crespillo-Gimez and J. Berq, “Soluble Tumour Necrosis Factor-Alpha Receptor I and Interleukin-6 as Markers of Activity in Thyrotoxic Graves’ Disease,” Hormone Metabolism and Research, Vol. 35, No. 7, 2003, pp. 427-433.
[18] J. J. Diez, A. Hernanz, S. Medina, C. Bayon and P. Iglesias, “Serum Concentrations of Tumour Necrosis FactorAlpha (TNF-alpha) and Soluble TNF-Alpha Receptor p55 in Patients with Hypothyroidism and Hyperthyroidism before and after Normalization of Thyroid Function,” Clinical Endocrinology (Oxford), Vol. 57, No. 4, 2002, pp. 515-521. doi:10.1046/j.1365-2265.2002.01629.x
[19] B. E. Van den Born, B. A. Dijikmans, H. H. Rooij, S. Lecessi and C. L. Verweij, “Chloroquine and Hyroxychloroquine Equally Effect Tumour Necrosis Factor Alpha, Interleukin 6 and Interferon Gamma by Peripheral Nuclear Cells,” Journal of Rheumatology, Vol. 24, No. 1, 1997, pp. 55-60.
[20] W. Ertel, M. H. Morrison, A. Ajala and I. H. Claudry, “Chloroquine Attenuate Haemorrhagic Shock-Induced Suppression of Kupfer Cell Antigen Presentation and Major Histocampatibility Complex Class Π Antigen Expression through Blockade of Tumour Necrosis Factor and Prostaglandin Release,” Blood, Vol. 78, No. 7,1991, pp. 17811788.
[21] W. B. Weqlicki, R. E. Stafford, A. M. Freedman, M. M. Cassidy and T. M. Philips, “Modulation of Cytokines and Myocardial Lesions by Vitamin E and Chloroquine in a Magnesium-Deficient Rat Model,” American Journal of Physiology, Vol. 264 No. 3, 1993, pp. 723-726.
[22] X. Zhu, W. Ertel, M. Ayala, M. H. Morrison, M. M. Perin and I. H. Chaudry, “Chloroquine Inhibits Macrophage Tumour Necrosis Factor-Alpha mRNA Transcription,” Immunology, Vol. 80, No. 1, 1993, pp. 122-126.
[23] J. Bondenson and R. Sundler, “Antimalarial Drugs Inhibit Phospholipase A2 Activation and Induction of Interleukin-1 Beta and Tumour Necrosis Factor Alpha in Macrophage: Implication for Their Mode of Action in Rheumatoid Arthritis,” General Pharmacology, Vol. 30 No. 3, 1998, pp. 357-366.
[24] G. Salmeron and P. E. Lipsky, “Immunosuppressive Potential of Antimalarials,” American Journal of Medicine, Vol. 75, No. 1, 1983, pp. 19-24.
[25] M. Nishimura, N. Hidaka, T. Akaza, K. Tdokoro and T. Juli, “Immunosuppressive Effect of Chloroquine: Potential Effectiveness for Treatment of Post-Transfusion Graftversus-Host Disease,” Transfusion Medecine, Vol. 8, No. 3, 1998, pp. 209-214.
[26] S. M. Weber and S. M. Levitz, “Chloroquine Antagonizes the Proinflamatory Cytokine Response to Opportunistic Fungi by Alkalizing the Fungi Phagolysosome,” Journal of Infectious Disease, Vol. 183, No. 6, 2001, pp. 935-942.
[27] S. M. Weber and S. M. Levitz, “Chloroquine Interferes with Lipopolysaccharide-Induced TNF-Alpha Gene Expression by a Nonlysosomic Mechanism,” Journal of Immunology, Vol. 165, No. 3, 2000, pp. 1534-1540.
[28] I. Karres, J. P. Kremer, L. Dietl, V. Steckholzer, M. Jochum and W. Ertel, “Chloroquine Inhibits Proinflamatory Cytokines Release into Human Whole Blood,” American Journal of Physiology, Vol. 274, No. 4, 1998, pp. 10581064.
[29] S. Picot, F. Peyron, A. Donadill, J. P. Vuilez, G. Barbe and P. Ambriose-Thomas, “Chloroquine Induced Inhibition of the Production of TNF but Not of Interleukin-6 Is Affected by Disruption of Iron Metabolism,” Immunology, Vol. 80, No. 1, 1993, pp. 127-133.
[30] L. Rosa, H. Silveria, E. Seixas, N. Roleo, G. Sntos-Gomes and V. Do Roserio, “The Effect of Chloroquine on the Production of Interferon-Gamma, IL-4, IL-6 and IL10 in Plasmodium Chabaudi Chabaudi Infected C57BL6 Mice,” Journal of Parasitology, Vol. 85, No. 5, 1999, pp. 956-960
[31] R. B. Landew, A. M. Mitenburg, F. C. Breedveld, M. R. Daha and B. A. Dijkmans, “Cyclosporine and Chloroquine Synergistically Inhibit Production of the Interferon-Gamma by CD4 Positive and CD8 Positive T Cells Clones Derived from a Patient with Rheumatoid Arthritis,” Journal of Rheumatology, Vol. 19, No. 9, 1992, pp. 1353-1357.
[32] E. A. Strtoer, M. I. Kochukov and W. Nikolaev, “The Lysosomal Proteolytic System and Thyroid Function Activity in Rats Administered Chloroquine,” Eksperimental’naia i Klinicheskaia Farmakologiia, Vol. 60, No. 4, 2000, pp. 50-52.
[33] S. Ito, T. Tamura and M. Nishikawa, “Effect of Desicated Thyroid, Prednisolone and Chloroquine on Goitre and Antibody Titre in Chronic Thyroiditis,” Metabolism, Vol. 17, No. 4, 1968, pp. 317-325.
[34] C. H. Van Deer Meer-Roosen, F. P. Maes and W. R. Faber, “A 19 Years Old Girl Presented with Coetaneous Lupus Erythematous and Hypothyroidism Developed a Thyrotoxic Crisis When Chloroquine Therapy Was Discontinued,” British Journal of Dermatology, Vol. 10, No. 1, 1979, pp. 91-92.
[35] A. Soltani, A. Moayyeri and F. Azizi, “Combination Therapy of Chloroquine and Methimazole in Graves’ Disease: A Pilot Randomized Controlled Trial,” Biomedicine & Pharmacotherapy, Vol. 61, No. 4, 2007, pp. 241243. doi:10.1016/j.biopha.2007.01.001
[36] F. Bernier-Valentin, Z. Kostrouch, R. Rabilloud, Y. Munari-Silem and B. Rousett, “Coated Vesicles from Thyroid Cells Carry Iodinated Thyroglobulin Molecules,” Journal of Biological Chemistry, Vol. 265, No. 28, 1990, pp. 17373-17380.
[37] F. Bernier-Valentin, Z. Kostrouch, Z. R. Rabilloud and B. Rousset, “Analysis of the Thyroglobulin Internalization Process Using in Vitro Reconstituted Thyroid Follicles: Evidence for a Coated Vesicle-Dependent Endocytic Pathway,” Endocrinology, Vol. 129, No. 4, 1991, pp. 21942201.
[38] Z. Kostrouch, Y. Munari-Silem and F. Rajas, “Thyroglobulin Internalized by Thyrocytes Passes through Early and Late Endosomes,” Endocrinology, Vol. 129, No. 4, 1991, pp. 2202-2211.
[39] M. Marinò, S. Lisi, A. Pinchera, L. Chiovato and R. T. McCluskey, “Targeting of Thymoglobulin to Transcytosis Following Megalin Mediated Endocytosis: Evidence for a Preferential pH Independent Pathway,” Journal of Endocrinological Investigation, Vol. 26, No. 3, 2003, pp. 222-229.
[40] J. Unqer, P. Ketelbant and J. E. Dumont, “Inhibition by Lysosomotropic Amines of Dog Thyroid Secretion in Vitro,” Endocrinology, Vol. 116, No. 3, 1985, pp. 958-965.
[41] Y. Kasuga, S. Matsybayashi, F. Akasu, N. Miller, S. Jamieson and R. Volpe, “Effect of Recombinant Human Interleukin-2 and Tumour Necrosis Factor-α with or without Interferon Gamma on Human Thyroid Tissue from Patients with Graves’ Disease and from Normal Subjects Xenografted into Nude Mice,” Journal of Clinical Endocrinology and Metabolism, Vol. 72, No. 6, 1991, pp. 12961301.
[42] M. Bucema, I. Todd, U. Deuss, L. Hammond, R. Mirakian, R. Pujol-Borrel and J. F. Bottazzo, “Influences of Tumor Necrosis Factor-α on the Modulation by Interferon-γ of HLA Class II Molecules in Human Thyroid Cells and Its Effect on Interferon-γ Binding,” Journal of Clinical Endocrinology and Metabolism, Vol. 69, No. 2, 1989, pp. 433-439.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.